Quantification of Human Cytomegalovirus DNA in Bone Marrow Transplant Recipients by Real-Time PCR (original) (raw)

Abstract

A real-time PCR assay was developed to quantify human cytomegalovirus (CMV) DNA in peripheral blood leukocytes (PBLs) of bone marrow transplantation patients. Unlike other teams, we quantified CMV and the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene using a plasmid containing both sequences as an external standard. Tenfold serial dilutions of this plasmid yielded overlapping standard curves that allowed the quantification of CMV and GAPDH gene copies in an efficient and accurate manner. Sequential blood samples (164 specimens) were collected from 16 patients. PBLs were tested by the pp65 antigenemia assay and quantitative CMV and GAPDH gene PCRs. CMV DNA was detected by PCR in 13 patients a mean of 15 days prior to the appearance of antigenemia. The administration of anti-CMV drugs led to a rapid decrease in the numbers of viral copies and positive nuclei. Real-time PCR assay results correlated with those of the CMV pp65 antigenemia assay (P < 0.00001). The TaqMan assay may be a useful tool for rapid quantification of CMV infection and for monitoring of CMV reactivation in bone marrow transplantation recipients.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (22)

  1. Blank, B. S., P. L. Meenhorst, J. W. Mulder, G. J. Weverling, H. Putter, W. Pauw, W. C. Van Dijk, P. Smits, S. Lie-A-Ling, P. Reiss, and J. M. Lange. 2000. Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immu- nodeficiency virus-infected patients. J. Clin. Microbiol. 38:563-569.
  2. Boeckh, M., T. A. Gooley, D. Myerson, T. Cunningham, G. Schoch, and R. A. Bowden. 1996. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 10:4063-4071.
  3. Einsele, H., M. Steidle, A. Vallbracht, J. G. Saal, G. Ehninger, and C. A. Muller. 1991. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain re- action technique. Blood 77:1104-1110.
  4. Fajac, A., F. Stephan, A. Ibrahim, E. Gautier, J. F. Bernaudin, and J. L. Pico. 1997. Value of cytomegalovirus detection by PCR in bronchoalveolar lavage routinely performed in asymptomatic bone marrow recipients. Bone Marrow Transplant. 20:581-585.
  5. Gault, E., Y. Michel, A. Dehee, C. Belabani, J. Nicolas, and A. Garbarg- Chenon. 2001. Quantification of human cytomegalovirus DNA by real-time PCR. J. Clin. Microbiol. 39:772-775.
  6. Gerna, G., D. Zipeto, E. Percivalle, M. Parea, M. G. Revello, R. Maccario, G. Peri, and G. Milanesi. 1992. Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in poly- morphonuclear leukocytes from viremic patients. J. Infect. Dis. 166:1236- 1244.
  7. Gleaves, C. A., T. H. Smith, E. A. Shuster, and G. R. Person. 1984. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine speci- mens by using low-speed centrifugation and monoclonal antibody to an early antigen. J. Clin. Microbiol. 19:917-919.
  8. Goodrich, J. M., M. Mori, C. A. Gleaves, C. Du Mond, M. Cays, D. F. Ebeling, W. C. Buhles, B. DeArmond, and J. D. Meyers. 1991. Early treat- ment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N. Engl. J. Med. 325:1601-1607.
  9. Goodrich, J. M., R. A. Bowden, L. Fisher, C. Keller, G. Schoch, and J. D. Meyers. 1993. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118:173-178.
  10. Hebart, H., D. Gamer, J. Loeffer, C. Mueller, C. Sinzger, G. Jahn, P. Bader, T. Klingebiel, L. Kanz, and H. Einsele. 1998. Evaluation of Murex CMV DNA hybrid capture assay for the detection and quantification of cytomeg- alovirus infection in patients following allogeneic stem cell transplantation. J. Clin. Microbiol. 36:1333-1337.
  11. Ibrahim, A., E. Gautier, S. Roittmann, J. H. Bourhis, A. Fajac, I. Charnoz, P. Terrier, J. M. Salord, C. Tancrede, M. Hayat, J. F. Bernaudin, and J. L. Pico. 1997. Should cytomegalovirus be tested for in both blood and bron- choalveolar lavage fluid of patients at a high risk of CMV pneumonia after bone marrow transplantation? Br J. Haematol. 98:222-227.
  12. Ljungman, P., K. Lore, J. Aschan, S. Klaesson, I. Lewensohn-Fuchs, B. Lonnqvist, O. Ringden, J. Winiarski, and A. Ehrnst. 1996. Use of a semi- quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive anti- viral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 17:583-587.
  13. Machida, U., M. Kami, T. Fukui, Y. Kazuyama, M. Kinoshita, Y. Tanaka, Y. Kanda, S. Ogawa, H. Honda, S. Chiba, K. Mitani, Y. Muto, K. Osumi, S. Kimura, and H. Hirai. 2000. Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplan- tation. J. Clin. Microbiol. 38:2536-2542.
  14. Nazzari, C., A. Gaeta, M. Lazzarini, T. D. Castelli, and C. Mancini. 2000. Multiplex polymerase chain reaction for the evaluation of cytomegalovirus DNA load in organ transplant recipients. J. Med. Virol. 61:251-258.
  15. Perol, Y., V. Caro, and M. C. Mazeron. 1993. Cytomegalovirus antigenemia assay: therapeutic usefulness and biological significance. Nouv. Rev. Fr. Hematol. 35:95-98.
  16. Reusser, P., J. G. Gambertoglio, K. Lilleby, and J. D. Meyers. 1992. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autolo- gous and allogeneic marrow transplant recipients. J. Infect. Dis. 166:473- 479.
  17. Schmidt, G. M., D. A. Horak, J. C. Niland, S. R. Duncan, S. J. Forman, and J. A. Zaia. 1991. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. The City of Hope-Stanford-Syntex CMV Study Group. N. Engl. J. Med. 324:1005-1011.
  18. Seropian, S., D. Ferguson, E. Salloum, D. Cooper, and M. L. Landry. 1998. Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant. Bone Marrow Trans- plant. 22:507-509.
  19. Tanaka, N., H. Kimura, K. Iida, Y. Saito, I. Tsuge, A. Yoshimi, T. Mat- suyama, and T. Morishima. 2000. Quantitative analysis of cytomegalovirus load using a real-time PCR assay. J. Med Virol. 60:455-462.
  20. The, T. H., W. Van der Bij, A. P. Van den Berg, M. Van der Giessen, J. Weits, H. G. Sprenger, and W. J. Van Son. 1990. Cytomegalovirus antigenemia. Rev. Infect. Dis. 12(Suppl. 7):S734-S744.
  21. Weber, B., U. Nestler, W. Ernst, H. Rabenau, J. Braner, A. Birkenbach, E. H. Scheuermann, W. Schoeppe, and H. W. Doerr. 1994. Low correlation of human cytomegalovirus DNA amplification by polymerase chain reaction with cytomegalovirus disease in organ transplant recipients. J. Med. Virol. 43:187-193.
  22. Yun, Z., I. Lewensohn-Fuchs, P. Ljungman, and A. Vahlne. 2000. Real-time monitoring of cytomegalovirus infections after stem cell transplantation us- ing the TaqMan polymerase chain reaction assays. Transplantation 69:1733- 1736.